COVID-19 led to 900,000 hospitalizations in the U.S. in 2023 alone. There are several types of COVID-19 tests approved in the U.S. Testing may consist of COVID-19 only or multiplex (which includes COVID-19 and an additional target such as influenza) and may involve molecular or antigen methods. We examined utilization and reimbursement patterns of COVID-19 tests in the commercially-insured population.

This report was commissioned by Pfizer, Inc.